Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane N Winter

Showing results (31-40 of 142) with videos related to

Pageof 15
Sort By:
The Oncologist|May 4, 2023
Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational StudyPeter G Doukas, Frederique St Pierre, Reem Karmali, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 12, 2023
Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6Hira Mian, Jolie Ringash, Ralph Meyer, et al.
Leukemia & Lymphoma|August 22, 2012
Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidationRupali Roy, Andrew M Evens, David Patton, et al.
British Journal of Haematology|August 10, 2013
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomasAndrew M Evens, Steven T Rosen, Irene Helenowski, et al.
Blood Advances|June 16, 2023
Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphomaJia Ruan, Jasmine Zain, Brett Palmer, et al.
Leukemia Research|September 17, 2022
Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 studyShuo Ma, Steven T Rosen, Maria Winqvist, et al.
British Journal of Haematology|December 17, 2016
The impact of fertility preservation on treatment delay and progression-free survival in women with lymphoma: a single-centre experiencePamela B Allen, Mary Ellen Pavone, Kristin N Smith, et al.
Journal of the American College of Radiology : JACR|September 25, 2008
ACR Appropriateness Criteria on Hodgkin's lymphoma: favorable prognosis stage I and IIPrajnan Das, Andrea Ng, Louis S Constine, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 11, 2010
A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphomaOmer N Koç, Charles Redfern, Peter H Wiernik, et al.
British Journal of Haematology|April 23, 2010
Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanismsSavita Bhalla, Leo I Gordon, Kevin David, et al.
Pageof 15

Showing results (31-40 of 142) with videos related to

Sort By:
Pageof 15
The Oncologist|May 4, 2023
Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational StudyPeter G Doukas, Frederique St Pierre, Reem Karmali, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 12, 2023
Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6Hira Mian, Jolie Ringash, Ralph Meyer, et al.
Leukemia & Lymphoma|August 22, 2012
Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidationRupali Roy, Andrew M Evens, David Patton, et al.
British Journal of Haematology|August 10, 2013
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomasAndrew M Evens, Steven T Rosen, Irene Helenowski, et al.
Blood Advances|June 16, 2023
Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphomaJia Ruan, Jasmine Zain, Brett Palmer, et al.
Leukemia Research|September 17, 2022
Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 studyShuo Ma, Steven T Rosen, Maria Winqvist, et al.
British Journal of Haematology|December 17, 2016
The impact of fertility preservation on treatment delay and progression-free survival in women with lymphoma: a single-centre experiencePamela B Allen, Mary Ellen Pavone, Kristin N Smith, et al.
Journal of the American College of Radiology : JACR|September 25, 2008
ACR Appropriateness Criteria on Hodgkin's lymphoma: favorable prognosis stage I and IIPrajnan Das, Andrea Ng, Louis S Constine, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 11, 2010
A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphomaOmer N Koç, Charles Redfern, Peter H Wiernik, et al.
British Journal of Haematology|April 23, 2010
Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanismsSavita Bhalla, Leo I Gordon, Kevin David, et al.
Pageof 15